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Abstract: This review summarizes recent developments in radiocarbon tracer technology and
applications. Technologies covered include accelerator mass spectrometry (AMS), including
conversion of samples to graphite, and rapid combustion to carbon dioxide to enable direct liquid
sample analysis, coupling to HPLC for real-time AMS analysis, and combined molecular mass
spectrometry and AMS for analyte identification and quantitation. Laser-based alternatives, such as
cavity ring down spectrometry, are emerging to enable lower cost, higher throughput measurements
of biological samples. Applications covered include radiocarbon dating, use of environmental
atomic bomb pulse radiocarbon content for cell and protein age determination and turnover studies,
and carbon source identification. Low dose toxicology applications reviewed include studies of
naphthalene-DNA adduct formation, benzo[a]pyrene pharmacokinetics in humans, and triclocarban
exposure and risk assessment. Cancer-related studies covered include the use of radiocarbon-labeled
cells for better defining mechanisms of metastasis and the use of drug-DNA adducts as predictive
biomarkers of response to chemotherapy.
Keywords: accelerator mass spectrometry; cavity ring down spectrophotometry; radiocarbon;
naphthalene; benzo[a]pyrene; cell turnover; triclocarban; metastasis; DNA adducts; biomarkers
1. Introduction
Radioisotopes play an important role in advancing our knowledge in the biomedical sciences.
The applications are broad, ranging from positron-emission-tomography to the use of scintillation
radiometry for determining protein turnover rates [1–4]. Nearly all radioisotope technologies detect
and quantify radioisotopes based on the detection of a nuclear decay event. However, for many
radioisotopes, this is an inefficient process, resulting in the need for high levels of radioactivity that
are costly and require extensive safety precautions. For this reason, many investigators have avoided
using radioisotopes in their research [5].
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Radiocarbon-labeled drugs are often used to study absorption, distribution, metabolism,
and excretion (ADME) in animals and humans. The resulting data aids in defining the metabolic fate
of the drug and informs the usefulness of comparing pharmacokinetics (PK) and metabolism in animal
models to humans. Radiocarbon (14C) is often the label of choice because it is stable enough to be
incorporated into virtually any carbon position on a given molecule using standard organic chemical
synthesis methodology, yet it is active enough of a β-emitter to be detected by standard techniques,
such as liquid scintillation counting (LSC) [6]. The use of 4C has limitations due to the long half-life of
this isotope (5740 years), which renders LCS counting of less than 5 to 10 picomoles 4C/mL of plasma or
urine impractical [2], which renders the assessment of drugs at microgram doses impossible (for highly
potent drugs or microdose studies).
Accelerator mass spectrometry (AMS) is a highly sensitive technology for quantifying radioisotopes
that has more recently been applied to the biomedical sciences. Quantification of radioisotopes with
AMS does not rely on the nuclear decay, but rather on the direct quantification of the isotopic nuclei
through mass spectrometry (reviewed in [7]). This provides much greater sensitivity for isotope
detection (103 to 109 times greater than decay counting), leading to the use of lower chemical and
radioisotope doses and the analysis of smaller samples, which enables studies to be performed safely
in humans, using exposures that are environmentally or therapeutically relevant while generating little
radioactive waste. Most biomedical AMS studies have employed radiocarbon (14C) as the radiolabel,
although the capability exists for detecting other isotopes, including 3H, 26Al, 41Ca, 10Be 36Cl, 59Ni,
63Ni, and 129I. Both 14C and 3H are commonly used in tracing studies because they can be readily
incorporated into organic molecules, either synthetically or biosynthetically. This review will focus
on the direct detection of 14C from biological samples, either using AMS or laser-based systems that
do not rely on decay counting. Technologies that are reviewed herein include the conversion of
samples to graphite or carbon dioxide, followed by direct AMS analysis, combined AMS/ion trap mass
spectrometry, and laser-based quantitation, along with examples of applications of these technologies
to molecular toxicology, cell turnover, metastasis, and chemotherapy drug resistance.
2. Technology
2.1. Graphite
The most important considerations in preparing samples for radiocarbon analysis are the amount
of radioisotope in each sample, preventing contamination, and knowing the sources and amounts of
any carbon introduced during processing. Numerous precautions need to be in place throughout the
procedure to ensure the amount of isotope present is within the dynamic range of the spectrometer
and to minimize the potential for contamination to ensure that the isotope detected in the sample is
associated with the labeled compound under investigation. The sample of interest, for example, blood,
DNA, or high-performance liquid chromatography (HPLC) fractions, must be converted to a form that
is compatible with the ion source of the instrument. The standard procedure for the preparation of
14C-labled biological samples for AMS analysis is the conversion of the biological sample to graphite.
This homogeneous state ensures uniformity and comparability between samples and standards that
are compatible with the AMS ion source [8]. Graphite samples for AMS quantification are most
commonly prepared by the reduction of carbon dioxide by hydrogen onto a catalytic iron or cobalt
surface at temperatures around 500 ◦C [9–13]. Reduction of CO2 to a filamentous graphite using septa
sealed vials proceeds rapidly and yields of >95% are routinely obtained. Samples containing as little
as 20 µg of carbon can be converted to graphite [14]. The graphite produces intense, long-lasting
negative ion beams upon introduction to the cesium sputter ion source with extremely small isotopic
and mass fractionation. The graphite-preparation stage is the rate-limiting step in AMS studies and
precludes real-time analyses, such as those possible with typical LC/MS methods. However, the recent
development of a gas-accepting ion source has eliminated the need for graphite in some applications.
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2.2. Gas Ionization
The elimination of matrix effects in the 14C-AMS analysis of biochemicals requires the physical
and chemical equivalence for all measured carbon atoms. Additionally, almost all AMS systems
use a cesium sputter ion source to generate negative ions and, consequently, methods for preparing
biochemical samples for analysis were adapted from well-developed techniques used for geochronology
studies. Subsequently, biochemical samples for AMS analysis are first combusted to CO2, followed by
reduction to graphite. While these methods have proven to be very successful, the technique suffers
from low throughput and requires significant and adroit human handling. The routine preparation
of graphitic biochemical samples requires at least 0.5 mg of carbon and limits sensitivity to ~2 amol
14C/mg C (~0.3 mdpm/mg C). This requires that the analysis of biochemical mixtures separated using
U/HPLC must be collected as discrete fractions with each treated as an individual sample. Samples
from a single 30-minute LC trace can require several days to prepare and take over eight hours of
AMS analysis time, costing several thousands of dollars, all of which increases if a higher resolution
and/or duplicate analysis is required. In some instances, the number of samples from an LC trace
can be reduced by collecting only fractions containing the peak(s) of interest and pooling fractions of
“uninteresting regions”. However, this is not always a viable option, especially in instances where an
entire metabolite profile is required.
Analysis systems that are compatible with the direct input of biochemical separation
instrumentation, such as liquid chromatography, would allow real-time analysis, leading to increased
resolution, minimal handling, and the ability to do molecule-specific tracing of small samples.
This approach involves the direct introduction of carbon as CO2 into the ion source. This sample
form is more efficient for the small samples common to biochemical research and allows for the
direct interfacing of separation instrumentation to AMS. A moving wire interface, developed at
Lawrence Livermore National Laboratory, provides one solution [15–17]. Briefly, the output of the
HPLC is jetted onto a moving wire, which is pulled through a drying oven to remove the volatile
solvent before introduction into a high temperature oven where the remaining analyte is combusted.
The resultant CO2 gas is then carried in a helium stream to the ion source of the AMS spectrometer for
14C-quantification of the separated analyte.
The moving wire interface was used to measure human plasma and urine metabolism
profiles following environmentally relevant exposures to the polycyclic aromatic hydrocarbons,
dibenzo[def,p]chrysene (DBC) (Figure 1) [18] and benzo[a]pyrene [19]. Due to their toxicity, doses to
healthy human volunteers were required to be kept as low as possible to minimize risk and the
metabolite levels recorded following HPLC separation were so low that they could only have been
measured as a CO2 gas.
Aside from the direct coupling of HPLC-AMS, CO2 gas-capable ion sources have also been coupled
with commercially available combustion furnaces for higher throughput analysis of discrete tracer
biochemical samples. In the system described by van Duijn et al., discrete samples containing at least
70 µg carbon and at least 0.52 amol of 14C are combusted using an elemental analyzer, with the resultant
CO2 captured and transferred to a gas-tight syringe for subsequent metering into a gas-accepting
hybrid ion source on a 1 MV HVEE AMS spectrometer [20]. Up to 200 samples may be measured
automatically in sequence, limited by the capacity of the sample target wheel of the ion source.
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process [13]. The recent development of the AMS liquid sample interface has enabled measurement 
of liquid samples without the need for graphitization [15,16,21]. The ability to measure liquid samples 
by AMS has also made it possible to integrate quantitative analysis with AMS sample measurements. 
The historical requirement for off-line speciation has been overcome by the recent development of a 
novel analytical technology that couples AMS directly with accurate mass spectrometry to enable 
real-time analysis of samples separated by high-performance liquid chromatography (HPLC). Based 
on the naming convention proposed by Sacks et al., this combined analytical method is referred to as 
parallel accelerator and molecular mass spectrometry (PAMMS) [22]. The LLNL PAMMS 
instrumentation is composed of a Waters Acquity H Class HPLC system, a Waters Xevo G2-XS QTOF 
instrument, an adjustable post-column flow splitter, a custom-built readout device, and the LS-AMS 
interface as depicted in the block diagram in Figure 2. 
 
Figure 1. UHPLC-AMS of [14C]-DBC and putative metabolites from human plasma 3 h after and
oral dose of 29 ng 14C-DBC. The use of unlabeled parent DBC and standards (DBC-(±)-11,12-diol
and DBC-(±)-11,12,13,14-tetraol) (top graph) allow for the identification of 14C peaks in plasma
(bottom graph).
2.3. Parallel Accelerator and Molecular Mass Spectrometry (PAMMS)
Historically, AMS measurements have required the use of off-line orthogonal analytical techniques
to speciate analytes measured by AMS. This limitation was based on the need to convert analytical
samples to graphite prior to AMS measurement, destroying all chemical information in the process [13].
The recent development of the AMS liquid sample interface has enabled measurement of liquid
samples without the need for graphitization [15,16,21]. The ability to measure liquid samples by
AMS has also made it possible to integrate quantitative analysis with AMS sa ple measurements.
The istorical requirement for off-line speciation has been overcome by the recent development of
a novel nalytical tech ol gy that cou l s AMS directly with ac urate mass sp trometry t enable
re l-time analysis of samples separated by high-performance liquid chromatogra hy (HPLC). Based
on the naming convention proposed by Sacks et al., this combined analytical method is referred
to as parallel accelerator and molecular mass spectrometry (PAMMS) [22]. The LLNL PAMMS
instrumentation is composed of a Waters Acquity H Class HPLC system, a Waters Xevo G2-XS QTOF
instrument, an adjustable post-column flow splitter, a custom-built readout device, and the LS-AMS
interface as depicted in the block diagram in Figure 2.
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PAMMS provides accurate mass measurement and tandem mass spectrometry for structural
elucidation of individual analytes separated by HPLC, but also measures stable carbon and carbon-14
in each separated analyte. PAMMS can therefore enable definitive identification, as well as quantitation,
of each separated analyte. For example, Figure 3 shows separation of glutamic acid in a mixture of
14C-labeled amino acids, and identification based on the exact mass and MS/MS fragmentation pattern.
PAMMS represents a significant innovation that takes advantage of the ability of AMS to measure
extremely low levels of 14C. The ability to use low concentrations of radiolabeled substrates in cells
and organisms at concentrations accessible by AMS allows quantification of metabolites without
perturbing normal metabolism and leads to more relevant quantification of metabolic rates and
pathways. Coupling the sensitive isotope detection abilities of AMS with accurate mass spectrometry to
identify analytes makes PAMMS a very powerful technique capable of providing both qualitative and
quantitative metabolic measurements. Such measurements can improve risk assessment for toxicants
and new therapeutic entities, deepen our understanding of xenobiotic and intermediary metabolism,
help understand interactions between critical molecular pathways, and improve efforts to model and
predict various metabolic and biological states when coupled with biocomputational methods.
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Figure 3. PAMMS analysis of carbon-14 labeled amino acid standards, showing (A) extracted ion
chromatogram (EIC) and (B) mass spectrum for glutamic acid.
2.4. CRDS
AMS’s complexity, large size, time consuming sample processing, and relatively high cost have
been an obstacle to the scientific community’s adoption of the method and its applications [23]. This has
led to several scientific groups exploring new ways to measure 14C [24–28]. One of these methods,
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cavity ringdown spectroscopy (CRDS), has demonstrated 14C sensitivities below contemporary levels.
Saturated-absorption cavity ring-down spectroscopy has achieved the greatest sensitivity of the CRDS
techniques, with a minimum-detection limit 60-times smaller than the requirement for basic-biological
studies [29].
Compared to AMS, CRDS is a simpler laser absorption technique for 14C detection, which leverages
a high-finesse optical cavity constructed with high-reflectivity mirrors (<1 ppm losses). This setup
permits gas–laser interaction path lengths equivalent to tens of kilometers and therefore, increased
sensitivity. A measurement starts by coupling resonant laser light into the optical cavity. This light
is then interrupted, and an exponential decay, or “ring-down”, is recorded on an optical detector.
Differences between the characteristic decay time of empty and sample filled cavities are used to
quantify the target species.
For biological studies utilizing 14C, carbonaceous analytes are combusted into CO2 and introduced
into the cavity. While CRDS does not have the sensitivity of AMS, several groups have demonstrated
the sensitivity to resolve natural background 14C levels [29–31]. Furthermore, validation studies have
been conducted, demonstrating CRDS produces results congruent with AMS when applied to duplicate
samples [30,32].
3. Applications
3.1. Radiocarbon Dating
14C is produced naturally in the upper atmosphere by nuclear reactions between cosmic radiation
and atmospheric gases, notably 14N. This natural 14C production rate varies slightly over time as
the Earth’s magnetic field changes and the cosmic ray fluxes fluctuate, but it has remained relatively
constant over most of recorded history, producing a natural source of 14CO2 that subsequently labels
every living thing on Earth as carbon moves through the food chain and carbon cycle. As long as a
plant or animal is alive, it is replenishing or increasing its carbon either directly from the atmosphere
(plants) or indirectly through consumption of plants and other animals. When an organism dies, the
carbon replacement ceases. Since 14C is radioactive (half-life T1/2 = 5730 y), the decrease in the 14C/C
concentration in tissue or biological structures compared to the atmospheric record can be used to
determine how long an organism has been dead. Willard Libby was awarded the 1960 Nobel Prize in
Chemistry for the development of radiocarbon dating [33].
3.2. Bomb Pulse Dating
Above-ground testing of nuclear weapons produced an anthropogenic spike in atmospheric
14CO2 and consequently produced a small, but measurable excess 14C label in every living thing on the
planet. This spike in 14C is generally called the radiocarbon bomb pulse. The pulse nearly doubled the
natural atmospheric 14C between 1955 and 1963, when the Limited Test Ban Treaty ended atmospheric,
under water, and outer space detonations by the United States, Soviet Union, and the United Kingdom.
Since the peak in 1963, atmospheric 14CO2 has been decreasing as carbon moves into the biosphere
and marine reservoirs and the burning of 14C-free fossil fuels drives the atmosphere to pre-bomb 14C
in 2018 to 2019. The date of biological molecule synthesis is highly correlated to atmospheric 14CO2,
so the atmospheric record is a chronometer of the molecular age or carbon source. Figure 4 depicts
the ratio of atmospheric radiocarbon to total carbon (14C/C) from 1900 to 2015 for the northern and
southern hemispheres based on compiled data [34]. The 14C/C differs between the hemispheres since
the weapons tests were conducted at relatively few locations, mostly in the northern hemisphere.
Before 1955 and after 1970, there is little difference in the annual averages of the hemispheres.
3.2.1. Carbon Source Determination
Since fossil-derived carbon is devoid of 14C, chemicals produced from petroleum do not contain
14C. Chemicals, vitamins, or food additives from a “natural” biological source possess the atmospheric
Toxics 2019, 7, 27 7 of 22
14CO2 signature. The 14C/C of an “all-natural” or “real” product should, therefore, be consistent with
100% biologically sourced material. If fossil-derived carbon is added to the product, the 14C/C is
depressed and easily measured by AMS. For example, in a 2011 study, real vanilla extracted from
vanilla beans possessed a contemporary radiocarbon signature of F14C = 1.059 ± 0.004 modern while
imitation vanilla had a F14C = 0.038 ± 0.001 modern [35,36]. The analysis of 14C can determine if a
food or personal care product has been adulterated with synthetic compounds. The technique can also
be used to determine if packaging contaminates a food product with an unintended or undesirable
compound. When a compound, such as phthalate, is found in a food product, 14C AMS analysis of the
purified compound can determine if it is naturally occurring in the food product, a result of leaching
from packaging, or a combination of these. Analyses of stilton cheese and butter for bis(2-ethylhexyl)
phthalate (DEHP) found that about 24% and 16% of the DEHP in the dairy products were of biological
origin and not from packaging materials [36,37].
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Figure 4. Annual averages of atmospheric 14C/C for the northern and southern hemispheres. Data before
1959 is derived from plant material while data from 1959 to present is derived from atmospheric CO2
collections and plant material. Data is reported in the ∆14C convention described by Stuiver and
Polach [38].
3.2.2. Structural and Pathological Protein Dating
The standard method to date bone found at archeological sites is to demineralize the bone, extract
the collagen, and use an ultrafiltration procedure to exclude smaller fragments, typically under 30 kD.
Collagen extraction works well because it is resistant to diagenesis (mineral exchange) of the mineral
component of bone while being protected by the mineral structure. Collagen is not static in bone,
it turns over as bone is remodeled throughout life, with the rates of turnover varying with age, type of
bone, position within a bone, physical activity, etc. Hence, the 14C of bone collagen is an integration
over a lifetime f variable inputs and outputs. The changing 14C/C in the bomb pulse enables studies
to determine th approxi ate turnove in bon [39] and opens forensic ap licati ns for roximating
the ages of skeletal remains [40].
Many structural proteins are found outside of bone. any f t in
the extra-cellular m trix (ECM) of organs, muscle, artil ge, ligaments, and vasculature. Human lung
parenchymal elastic fibers were shown to be the age of the person using 14C analyses and aspartate
racemization [41]. Radiocarbon dating of collagen from Achilles tendon and human articular cartilage
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shows growth and turnover through adolescence, but virtually no turnover during adulthood [42,43].
The eye lens continues to grow throughout life adding new cells to the outside in series of layers.
The crystallin proteins that provide much of the structure of the lens have been shown to have very
little turnover throughout life [44,45].
The chronological deposition of pathological structures is approachable by bomb pulse dating.
In the progression of Alzheimer’s Disease, the pathological structures of neurofibrillary tangles (NFT)
and senile plaques (SP) accumulate over time. Post mortem analyses of the separated structures
provided an average age, weighted by the rate of accumulation [46]. The average ages of the SP and NFT
predated clinical symptoms of Alzheimer’s disease in half the cases, indicating significant accumulation
before cognitive deterioration. In another example of long-term accumulation, arterial plaques that
restrict blood flow have also been shown to develop over decades [47,48]. The collagen extracted from
excised cerebral aneurysms tends to be about 3 years old, even for aneurysms followed by imaging for
years [49,50]. Additionally, subjects with risk factors of smoking, cocaine use, and hypertension had
collagen within a year old, indicating very rapid carbon turnover [49].
3.2.3. Cell Lifetime and Turnover
Genomic DNA only acquires significant new carbon at cell division, so the 14C/C of nuclear
DNA is a metric of the cell birth date [51]. Cell or nuclei surface markers can be utilized using
fluorescence activated cell sorting to isolate specific cell types for analyses. DNA is isolated from
specific cell populations, rinsed thoroughly to remove residual solvents, checked for purity using
UV/Vis absorbance, processed for AMS analyses using high precision natural radiocarbon preparation
techniques, and measured by AMS. Genomic DNA dating has been used to investigate neurogenesis
throughout many regions of the human brain [51–55]. The lack of bomb pulse carbon in neuronal DNA
of subjects born before 1955 indicated that DNA repair provides an insignificant amount of new carbon
after cell division [51]. It has also been used to determine that adipocytes turnover approximately
every 10 years [56] while the lipids they hold cycle every 1.5 years [57] and cardiomyocytes turnover
at a low rate [58]. Using bromodeoxyuridine (BrdU) and 14C/C analyses of DNA from pancreatic
β-cells, it was determined that insulin producing β-cells turnover at a 1% to 2% annual rate through
early adulthood and then cease to turnover after the age of 30 [59]. Antibody-secreting plasma cells
have been found to persist for decades in the intestines although antibodies last only several weeks
in circulation [60]. An alternative to dating DNA, dating histones established histone turnover as a
critical regulator of cell type-specific transcription and plasticity in the mammalian brain [61].
3.3. Tracking the Fate of Cells Labeled with [14C]Thymidine
Using a similar principle, we can also quantify the number of cancer cells that colonize distant
sites to form metastatic tumors [62]. In a recent publication, we have taken cancer cell lines with
varying metastatic potential, and labeled them in vitro with 14C-thymidine, such that we could identify
by AMS a single labeled cell among 1 million unlabeled cells. These labeled cells were introduced in
mice via various routes known to produce metastatic tumors (tail vein, TV; intracardiac, IC) and after
2-weeks or 12-weeks post injection, all organs were examined for the presence of metastatic tumors.
Whether visible tumors were present or not, total DNA was isolated from each organ, and the total
carbon was examined for the presence of 14C. The amounts of 14C detected per organ were referred
back to the amount of 14C present per cell, prior to injection into the mice, to determine how many
cells traveled to distant sites and initiated a metastatic tumor (Figure 5A).
Using this approach, we determined that less than 5% of human cancer cells injected into
immunodeficient mice form subcutaneous tumors, and even fewer cells initiate metastatic tumors.
Comparisons of metastatic site colonization between a highly metastatic (PC3) and a non-metastatic
(LnCap) prostate cancer cell line showed that PC3 cells colonize target tissues in greater quantities
at 2 weeks post-delivery, and by 12 weeks post-delivery, no 14C was detected in LnCap xenografts,
suggesting that all metastatic cells were cleared (Figure 5B). The 14C-signal correlated with the
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presence and the severity of metastatic tumors. AMS measurements of 14C-labeled cells provides a
highly-sensitive, quantitative assay to experimentally evaluate metastasis and colonization of target
tissues in xenograft mouse models. In the future, this approach could potentially be adapted to evaluate
tumor aggressiveness and assist in making informed decisions regarding treatment, towards a more
informed personalized therapy regimen.
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3.4. Low Dose Toxicity
One of the biggest advantages of AMS is the ability to perform low dose toxicity studies,
whic allow for the assessment of chemicals at environment lly relevant dose levels. Numerous
studies have used AMS to investigat the biodisposition of chemicals at low-dose human exposure
levels. Below are examples of some of these studies.
3.4.1. Naphthalene
Naphthalene (NA) is ubiquitous in both the indoor and outdoor environment. Common sources
of NA exposure include combustion products from vehicle emissions, biomass, cigarettes and wildfires,
mothballs, and house-hold block deodorizers. Naphthalene metabolites have been detected in the
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urine of nearly all children and adults tested, regardless of locale or occupation [63]. Further, studies
in children have shown increased chromosomal aberrations that correlate with urinary markers for
NA exposure, but these studies cannot establish a cause and effect relationship [63]. Furthermore,
NA exposure caused bronchiolar alveolar carcinomas in female mice and neuroblastomas in the nasal
epithelium of rats in the National Toxicology Program carcinogenesis bioassays [64,65]. The mechanism
of cancer initiation is unclear, however, so investigations of protein adducts, DNA adducts, and repair
tolerance [66,67] have been conducted using NA and its metabolite, 1,2 naphthoquinone (NQ).
Using well established techniques to obtain metabolically active, live tissue samples [68], freshly
micro-dissected respiratory tissues were incubated with NA or NQ at 250 µM, calculated as equivalent
to the tissue concentration obtained from exposure to the 10 ppm OSHA exposure limit for NA [69].
DNA adducts of NA and NQ are present in low levels, but protein adducts are much more
common [66,67]. The technique of ex vivo exposure of metabolically active tissue avoided making an
aerosol of a 14C-lableled toxic chemical and is applicable to other inhalation hazards.
3.4.2. Triclocarban
In a recently published study by Enright et al., the potential of an environmentally relevant
concentration of the antimicrobial, triclocarban (TCC), to transfer from the mother to the offspring
during development was evaluated using AMS [70]. Triclocarban is an antimicrobial found in many
personal care products (i.e., deodorants, soaps) and is among the top 10 most commonly detected
wastewater contaminants [71,72]. Given its prevalence in the environment, bioaccumulation of TCC
has been observed and reproductive effects have been noted as a result from exposure [73]. Exposure to
compounds, such as TCC, during development may have deleterious consequences to the developing
embryo and fetus, given their heightened sensitivity to perturbations in hormone levels and immature
protective mechanisms (i.e., liver metabolism, DNA repair mechanisms).
In this study, 14C-labeled TCC (100 nM) was administered to CD-1 mouse dams through their
drinking water up to gestation day 18, or from birth through to postnatal day (PND) 10.
Using AMS, the concentration of TCC was determined in both offspring and dams after exposure;
TCC transferred from mother to offspring both trans-placentally (0.005% ± 0.001% ingested dose/gram
(%ID/g) and through lactation (0.015% ID/g ± 0.002%) (Figure 6). The three-fold higher concentration in
offspring after exposure through lactation (p = 0.003) demonstrated that TCC readily transfers through
breast milk. After exposure through lactation, TCC exposed offspring were heavier in weight than
unexposed controls (p = 0.016 for PND21–56), with females more affected (11% increase) than males
(8.5% increase) (data not shown). Tissue accumulation was also quantified using AMS at 6 weeks post
exposure. TCC-related compounds were detected in tissues with higher concentrations observed in the
brain, heart, and fat. Quantitative real-time polymerase chain reaction (qPCR) of liver and fat tissue
suggested alterations of lipid metabolism in exposed female offspring; this was further supported
by an increase in fat pad weights and hepatic triglycerides. This was the first report quantifying
the translocation of an environmentally relevant concentration of TCC from mother to offspring;
this study was enabled by the high sensitivity of AMS. Taken together, our findings suggest that TCC
readily transfers from the mother to the offspring and that early-life exposure may interfere with lipid
metabolism, which can ultimately have implications for human health.
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3.4.3. Benzo[a]pyrene
Benzo[a]pyrene is a widely studied polycyclic aromatic hydrocarbon (PAH) that has been
shown to induce cardiovascular, developmental, immunological, and reproductive disorders in
model systems [74–76]. It has also been implicated as a human carcinogen and is an environmental
chemical of concern for human exposure according to the Agency for Toxic Substances and Disease
Registry [77]. Using the recently developed on-line UPLC-AMS interface with the gas accepting ion
source, human pharmacokinetic and metabolite profiles were determined from microdose exposures
of BaP. Five human volunteers were exposed to an oral dose of 46 ng (5 nCi) of 14C-BaP. Blood was
collected at given time intervals and pharmacokinetic and metabolite parameters were quantified
by AMS. At the dose used, BaP was fairly rapidly eliminated from the plasma and very little parent
compound was present in the plasma even at the earliest time point examined, indicating extensive
metabolism of BaP in these human subjects. The use of the UPLC-AMS together with the on-line gas
accepting ion source provided exquisite sensitivity (zepto-mole14C in biological samples), allowing for
the quantification of BaP plasma metabolites of BaP from exposure levels that were 5 to 15 times lower
than the estimated daily exposure to BaP [19].
3.5. Diagnostic Microdosing: Using Drug-DNA Adducts as Biomarkers of Chemotherapy Response
Chemotherapy drugs that modify DNA are a cornerstone of modern cancer treatment and are
used in nearly half of all cancer patients [78,79]. However, their efficacy is limited by severe side effects
and intrinsic or acquired drug resistance, eventually causing treatment failure [78,80–82]. AMS has
been used over the past 15 years for the measurement of drug–DNA interactions, and the resulting
data have been correlated with cell sensitivity and/or tumor response in mice and humans [83–96].
The overarching hypotheses of this work are that a threshold level of drug–DNA adducts are required
for cell killing and clinical response, and that microdose induced drug–DNA adduct levels are predictive
of the cellular capacity to achieve such a threshold upon therapeutic dosing. This approach, known as
“diagnostic microdosing”, has been initially demonstrated for platinum-based chemotherapy for the
treatment of solid tumors and induction chemotherapy for leukemia. Based on this and other work, it is
clear that for some chemotherapeutics, microdose-induced drug-DNA adducts are predictive of drug
sensitivity and response in cell culture and mouse tumor xenograft studies, along with an extension
of this effort to two pilot clinical studies focused on platinum-based chemotherapy (clinicaltrials.gov
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identifier NCT01261299 and NCT02569723) and a retrospective study on viably cryopreserved human
acute myeloid leukemia (AML) cells.
The diagnostic test protocol consists of four steps: (1) Creation of the individualized biomarkers
in patient cells by exposure to 14C-radiolabeled drugs, (2) isolation of DNA containing the biomarkers,
(3) determination of the 14C associated with the DNA via AMS analysis, and (4) comparison of the
patient’s drug-DNA adduct levels to a database of clinical responses in order to assign a predictive
score that indicates the probability of response.
Three key observations have included: (a) The level of drug-DNA adducts is generally
low in resistant cancers and high in responsive cancers, (b) microdosing predicts the level of
therapeutic-induced drug-DNA adducts, and (c) microdose-induced DNA adduct frequencies correlate
with cellular drug sensitivity and patient response. Selected published examples of these results are
summarized below.
3.5.1. Predicting Response to Platinum-Based Therapy with Microdosing
Figure 7 shows cell culture data for a set of six cancer cell lines dosed with [14C]carboplatin.
The drug interacts with DNA to form [14C]carboplatin-DNA “monoadducts” that are measurable by
AMS (Figure 7A). The monoadduct levels formed by microdoses were linearly proportional to those
formed by therapeutically relevant concentrations of the drug in the media over 24 hours (Figure 7B).
This is an important observation, since it implies that monoadduct levels formed from microdoses are
likely to be predictive of those induced by therapeutic doses in patients. Half of the cell lines tested had
carboplatin IC50 values below 100 µM (approximately the in vivo Cmax in humans) and were assigned
as “sensitive”. The remaining cell lines were designated as “resistant”. The sensitive and resistant cell
lines could be significantly differentiated based on microdose-induced carboplatin monoadduct levels
(Figure 7C), establishing proof of concept and justifying in vivo studies in mice and humans.
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(C) Sensitive cell lines (blue) have significantly higher carboplatin-DNA adduct levels than resistant
cancer cell lines (red).
Figure 8 shows data supporting the correlation between drug-DNA adduct levels and
in vivo treatment response in mice and humans. Mice bearing patient derived bladder tumor
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xenografts (PDX) were established as depicted in Figure 8A. There was a significant correlation
between microdose-induced carboplatin-DNA monoadduct levels and tumor growth inhibition of
platinum-based chemotherapy (Figure 8B). The pilot clinical trial accrued 10 bladder cancer patients
(stage II and higher), for whom platinum-based chemotherapy was administered. Patients were
administered approximately 1% of the therapeutic dose of [14C]carboplatin (a microdose), followed
by blood sampling within 24 h. DNA isolated from peripheral blood mononuclear cells (PBMC) was
assessed for carboplatin-DNA adduct levels by AMS. Within three months of the microdosing assay,
patients began standard of care chemotherapy regimens consisting of either cisplatin or carboplatin in
combination with other drugs (typically gemcitabine (GC) or methotrexate, vinblastine, and doxorubicin
(MVAC)). Patient response was determined at the time of cystectomy—typically after three cycles
of chemotherapy. A patient whose tumor burden in the bladder was reduced to pT1 or less was
considered a responder and a patient with a pT2 or greater tumor was considered a non-responder,
based on standard RECIST criteria [97]. The main endpoint of the study was to demonstrate a
significant difference in the mean drug-DNA adduct levels in PBMC (a surrogate for tumor tissue)
between responders and non-responders. Seven patients responded to chemotherapy (green circles),
whereas three patients showed disease progression (red squares) (Figure 8C). Responders exhibited
approximately 2-fold higher mean monoadduct levels (green line) than non-responders (red line)
(0.741 ± 0.346 vs. 0.283 ± 0.202 monoadducts/108 nt, respectively, p = 0.069). The drug-DNA adducts
were distributed in two distinct groups; high (0.941 ± 0.030 adducts per 108 nt) and low (0.266 ±
0.158 adducts per 108 nt) drug-DNA adduct levels with a statistically significant difference (p < 0.001).
All five patients in the high adduct level group responded to chemotherapy, which is a 100% positive
predictive value (PPV) for this group. The low adduct level group included three non-responders
and two responders. The results of this clinical trial show a clear trend for responders to have higher
Pt-DNA adduct levels 24 h after microdose administration, which supports the feasibility of patient
stratification by the diagnostic microdosing approach.
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3.5.2. Ex Vivo Diagnostic Microdosing for Predicting Response to 7 + 3 in AML Patients
In contrast to our previous efforts that focused on administering microdoses to patients, our more
recent work has focused on establishing proof-of-concept for a lab-based test in which biobanked or
fresh patient leukemia patient samples are dosed ex vivo. This change will allow us to overcome our
past difficulty in accruing patients that were unwilling to undergo IV administration of a radiolabeled
drug that would not provide a direct benefit (a non-interventional study). Furthermore, ex vivo
microdosing allows us to analyze multiple drug regimens on each patient sample. AML is ideal for
this concept, since it is a “liquid tumor” that can easily be accessed via a blood draw or bone marrow
biopsy, and is predominantly treated with two drugs that both interact with DNA.
The most effective therapy for AML is treatment with “induction chemotherapy” with two DNA
damaging drugs, including the antimetabolite, cytarabine (ARA-C), and an anthracycline, such as
daunorubicin (DNR) or idarubicin (IDA)—structures shown in Figure 9A. This regimen is known as
7 + 3 (7 days of continuous infusion ARA-C and 3 days of bolus DNR or IDA), and is the standard of
care for up to two thirds of AML patients. Treatment is started as soon as possible, typically within 5 to
7 days of diagnosis [98–101]. In addition, a subset of patients, including eligible younger patients and
relapsed or refractory (R/R) patients, can be treated with a combination of high-dose bolus ARA-C and
DNR or IDA, known as 3 + 4 [102–105]. Patients who are not eligible for 7 + 3 are typically placed on a
less toxic, ARA-C-containing regimen.
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Figure 9. Overview of the ex vivo “diagnostic microdosing” strategy. (A) Radiocarbon-labeled
cytarabine (ARA-C), idarubicin (IDA), or daunorubicin (DNR) bind to or are incorporated into AML
DNA in proportion to the cellular sensitivity to each drug. The resulting drug-DNA “adducts” can
be quantified by accelerator mass spectrometry (AMS). (B) Strategy for using in vitro microdosing to
predict AML patient response to 7 + 3 chemotherapy. Cells isolated from a blood draw or bone marrow
(fresh or viably cryopreserved) are briefly exposed to microdoses of each drug (triplicate wells per
drug) and assessed by mass spectrometry for quantitation of drug-DNA adduct levels as biomarkers of
clinical response to 7 + 3 induction chemotherapy.
Basic research into the significance of drug–DNA adducts in patients treated with anthracycline
deriv tives and antimetabolites similar to IDA [106] and ARA-C [107] chemotherapies has been
r ported, but none of these findings h ve been translated into clinical use [108–113]. Several reports
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have documented associations between drug–DNA adduct levels and clinical response and overall
survival [93,114]. These reports support the concept that a predictive stratification strategy can be used
to personalize chemotherapy if the capacity for cells to form high levels of drug-DNA adducts can be
predicted prior to the initiation of therapy. This body of work is being adapted to predicting AML
patient responses to 7 + 3 induction chemotherapy by implementing a diagnostic microdosing test
(Figure 9B).
After optimization of the protocols using cell culture experiments, we performed the diagnostic
microdosing protocol on 19 clinically annotated viably cryopreserved primary human AML samples,
including 10 responders and nine nonresponders to 7 + 3 induction chemotherapy, and DOX protocol
on 10 primary AML samples. When the primary samples were grouped based on patient response,
the responsive patients had higher mean drug–DNA adduct levels compared to the nonresponders for
all dosing regimens (Figure 10A–C). Statistical differences between the responders and nonresponders
were determined by unpaired t-tests with p < 0.05 as the statistically significant cutoff. The ARA-C- and
DOX-DNA adduct levels from each primary AML sample when plotted together showed a complete
separation in responders and nonresponders (Figure 10D—for 10 patients, since DOX- and ARA-C
combined adduct data are currently only available for 10 patients).
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and with patient response primary AML samples. These preliminary data show that the adduct levels
indeed correlate with resistance to doxorubicin and ARA-C.
4. Conclusions
Although much of the scientific demonstrations of the technological advances reviewed herein
for radiocarbon tracing are outside the scope of drug development and toxicology, there are clear
implications for such studies. Drug discovery, early clinical development, and studies to support
regulatory approval can all benefit from higher sensitivity and low-cost, high throughput radiotracer
technologies [115–118]. For example, in human studies, with much lower radiocarbon doses that are
currently used for HPLC-LSC, studies are not only technically desirable, but are also more ethical
since healthy human volunteers would have reduced radiation exposures. Absolute bioavailability
for oral compounds is another obvious application that would benefit from improved radiotracing
technologies. Although “standard” LC-MS is sufficient for PK and ADME studies of most drug
candidates, there will always be a subset of efficacious lead compounds that possess very high potency
at very low doses or with unusual PK or biodistribution that require radiolabel studies. Therefore,
drug development is likely to be more successful as radiotracer technologies become more accessible
and accepted. Radiocarbon tracer technology continues to evolve in order to increase throughput,
reduce cost and the amount of radioactivity needed, and broaden the types of applications that can
be accommodated. Basic science, environmental and molecular toxicology, and clinical translational
applications continue to be uniquely enabled by radiotracer studies, which are critical for advancing
our understanding of fundamental biology, protecting the environment, and improving human health.
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